A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Recruiting

Phase 3

Sponsor:

AstraZeneca

Code:

NCT06502366

Conditions

Asthma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BDA MDI HFO 160/180 μg

BDA MDI HFA 160/180 μg

Placebo MDI HFA

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information